Black Swift Group LLC Invests $1.21 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Black Swift Group LLC bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,000 shares of the medical equipment provider's stock, valued at approximately $1,207,000.

Several other institutional investors and hedge funds have also made changes to their positions in LNTH. Janney Montgomery Scott LLC increased its stake in Lantheus by 10.0% in the first quarter. Janney Montgomery Scott LLC now owns 8,804 shares of the medical equipment provider's stock valued at $548,000 after purchasing an additional 799 shares during the period. Envestnet Portfolio Solutions Inc. raised its stake in Lantheus by 9.0% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 5,369 shares of the medical equipment provider's stock valued at $334,000 after acquiring an additional 442 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Lantheus during the 1st quarter valued at approximately $105,000. Russell Investments Group Ltd. lifted its position in Lantheus by 10.4% during the 1st quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider's stock worth $2,347,000 after acquiring an additional 3,560 shares during the period. Finally, ProShare Advisors LLC grew its stake in shares of Lantheus by 4.7% in the 1st quarter. ProShare Advisors LLC now owns 15,567 shares of the medical equipment provider's stock valued at $969,000 after purchasing an additional 698 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on LNTH shares. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective on the stock. JMP Securities cut their price target on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a report on Thursday, November 7th. B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. StockNews.com raised Lantheus from a "hold" rating to a "buy" rating in a research note on Friday, November 8th. Finally, Truist Financial restated a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, Lantheus has a consensus rating of "Moderate Buy" and a consensus target price of $122.50.

Lantheus Price Performance

LNTH traded up $1.08 during midday trading on Thursday, reaching $80.84. 1,588,956 shares of the company's stock were exchanged, compared to its average volume of 1,009,429. The business's 50-day moving average price is $105.46 and its 200 day moving average price is $96.17. The stock has a market capitalization of $5.62 billion, a PE ratio of 13.45 and a beta of 0.51. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.